From the publishers of JADPRO

Acute Lymphoblastic Leukemia Resource Center

Advertisement

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: The DELPHINUS study

Last Updated: Wednesday, January 22, 2025

This phase 2 DELPHINUS study evaluated daratumumab (16 mg/kg IV) with chemotherapy in relapsed/refractory ALL/LL patients. While B-cell ALL cohorts showed no CRs, T-cell ALL/LL cohorts had CR rates of 41.7%-60.0%. Daratumumab was safe, achieved high HSCT rates (30%-75%), and supported successful bridging to transplantation in T-cell ALL/LL patients.

Blood
Advertisement
News & Literature Highlights

Discover Oncology

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: A case series and literature review

Frontiers in Oncology

Impact of standardized immunophenotyping and MRD monitoring on early mortality reduction in childhood leukemia: A step towards addressing healthcare disparities in vulnerable populations from Southern Mexico

Clinical and Experimental Pediatrics

Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/ refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis

Medical Journal, Armed Forces India

Bone mineral density in childhood acute lymphoblastic leukaemia survivors and factors affecting it

Blood Advances

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Pediatrics International: Official Journal of the Japan Pediatric Society

Safety and efficacy of sedation for pediatric patients with cancer and developmental disabilities

BMC Ophthalmology

Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution

Leukemia

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-center, single-arm, phase 2 trial

Cancer

Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Clinical Laboratory

T-acute lymphoblastic leukemia/lymphoma manifesting as acute renal failure

Advertisement
Advertisement